# Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

> **NCT05512949** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 229 (actual)

## Conditions studied

- Monkeypox

## Interventions

- **BIOLOGICAL:** JYNNEOS

## Key facts

- **NCT ID:** NCT05512949
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-09
- **Primary completion:** 2023-10-12
- **Final completion:** 2025-02-24
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512949, "Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05512949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*